+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Adjuvant chemotherapy for non-small cell lung cancer. WJSG: West Japan Study Group for Lung Cancer Surgery



Adjuvant chemotherapy for non-small cell lung cancer. WJSG: West Japan Study Group for Lung Cancer Surgery



Gan to Kagaku Ryoho. Cancer and ChemoTherapy 21(Suppl. 3): 356-361



Surgery is the treatment of choice for non-small cell lung cancer (NSCLC). But even for potentially curative resection, patients often die of relapse, and five-year survival rates are about 70 percent even for stage I patients. Hence, considering the necessity of post-operative adjuvant chemotherapy, many comparative trials have been undertaken internationally as well. It is important to undertake randomized comparative trials with the survival endpoint, comparing with surgery alone, and to assess the efficacy of adjuvant chemotherapy. Cisplatin-based regimens, which are effective for anti-tumor results as a surrogate endpoint, are used routinely in adjuvant settings. However, the reliability of these adjuvant trials is not yet verified at present. This paper reports on the adjuvant chemotherapy results for NSCLC patients who had undergone a completely curative resection, considering QOL (Quality of Life) and immunity.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 045175991

Download citation: RISBibTeXText

PMID: 7986115


Related references

Postoperative adjuvant chemotherapy with PVM (Cisplatin + Vindesine + Mitomycin C) and UFT (Uracil + Tegaful) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial. West Japan Study Group for lung cancer surgery (WJSG). European Journal of Cardio-Thoracic Surgery 15(4): 438-443, 1999

A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG)--the 4th study. Annals of Oncology 16(1): 75-80, 2004

A randomized phase III trial of adjuvant chemotherapy with cisplatin and vindesine followed by UFT for completely resected pathologic (p-) stage IIIA-N2 non-small cell lung cancer (NSCLC): West Japan Study Group for Lung Cancer Surgery (WJSG) - the 5 th Study. Journal of Clinical Oncology 23(16_Suppl): 7262-7262, 2016

Postoperative adjuvant chemotherapy for non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery. The Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy. Oncology 11(9 Suppl 10): 98-102, 1998

Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery. Journal of Clinical Oncology 14(4): 1048-1054, 1996

A randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer (the second cooperative study). The Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan). European Journal of Surgical Oncology 21(1): 69-77, 1995

Postoperative oral administration of UFT for completely resected pathologic stage I non-small cell lung cancer The West Japan Study Group for Lung Cancer Surgery , the 4th study. European Journal of Cancer 37(Suppl. 6): S29, 2001

Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group. Cancer Prevention and Control 1(5): 366-378, 1998

Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group. Journal of the National Cancer Institute 85(4): 299-306, 1993

A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group. British Journal of Cancer 68(4): 813-818, 1993

Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial. International Journal of Clinical Oncology 15(6): 583-587, 2011

Feasibility of adjuvant chemotherapy with S-1 plus carboplatin followed by single-agent maintenance therapy with S-1 for completely resected non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 1001. International Journal of Clinical Oncology 22(2): 274-282, 2016

Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. Journal of Clinical Oncology 16(3): 1068-1074, 1998

Phase II study of 3-hour infusion of paclitaxel in patients with previously untreated stage III and IV non-small cell lung cancer. West Japan Lung Cancer Group. Oncology 54(4): 298-303, 1997

Neoadjuvant chemotherapy followed by preoperative radiochemotherapy (hfRTCT) plus surgery or surgery plus postoperative radiotherapy in stage III non-small cell lung cancer: Results of a randomized phase III trial of the German lung cancer cooperative group. International Journal of Radiation Oncology*biology*physics 60: S130-S130, 2004